ColdKingdom

Associate Professor in bioinformatics; data science, immunogenomics; cancer genomics, metabolic disease research

[The Lancet @TheLancet]

Obesity is increasingly addressed with disease-modifying medications, with benefits that extend across other conditions.

A Review in @TheLancetEndo explores the multisystem benefits of obesity medications beyond weight loss: https://t.co/elmnTFscDF

[Cell Metabolism @Cell_Metabolism]

GLP-1 and MASH: When weight loss isn’t the whole story https://t.co/h44bxcKmeW

[Jason Buenrostro @JD_Buenrostro]

A must read! Predicting health trajectories form electronic health records:

https://t.co/dSrDMQQ2vo

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

New online! Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus https://t.co/SR7KlseOYz

[Gastroenterology & Endoscopy News @gastroendonews]

In liver disease care, timing matters—but so does trajectory.
New studies are exploring whether changes in noninvasive fibrosis markers over just one year can help identify which patients are quietly progressing toward worse outcomes: https://t.co/zUwaDy2L62 #GI #liverdisease

[Cell Metabolism @Cell_Metabolism]

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors https://t.co/YDns4diYIG

[NEJM @NEJM]

Correspondence: Artificial Intelligence and Detection of Hirschsprung Disease https://t.co/hXsWzGXrnu

#AIinMedicine

[Eric Topol @EricTopol]

As we've seen with the heart, kidney and osteoarthritis, some of the GLP-1 drug benefit for liver disease (MASH) is direct, independent of weight loss @Cell_Metabolism
https://t.co/pZtA1dlgyg

[Nature Portfolio @NaturePortfolio]

A study published in Nature Communications highlights the biological diversity of severe pneumonia, uncovering distinct phenotypes that could guide personalized treatment strategies based on specific immune responses and clinical features. https://t.co/WMKa3xMsSq

[Sociedad Española de Patología Digestiva (SEPD) @sepdigestiva]

Mecanismos biológicos que relacionan la obesidad con el cáncer. ✅ https://t.co/OTlRHkJlsA

[Diabetologia @DiabetologiaJnl]

Beyond lipids, altered #GlucoseMetabolism and hormonal dysregulation drive #MASLD progression to #MASH via adipokine-mediated signalling, highlighting #LiverDisease as a multi-organ disorder driven by multi-substrate metabolic reprogramming https://t.co/JfTMDwf0QH 🔓️ #Fibrosis

[Michael Weintraub, MD @MWeintraubMD]

💉 Survodutide, a dual GLP-1/glucagon agonist, with Phase 3 results specifically in those with metabolic-associated steatotic liver disease (MASLD).

⬇️ 84% of survodutide group met primary endpoint of >30% liver fat content reduction by MRI, compared to 24% of placebo.

⬇️ Survodutide group had 12% weight reduction vs. 1% with placebo.

🔑 Glucagon agonism likely has direct liver benefits, independent of weight loss

📊 SYNCHRONIZE-MASLD published in Nature Medicine: https://t.co/ZOJ1HILgAH

[Scott Isaacs @scottisaacsmd]

New review on epidemiology of cardiometabolic multiple long-term conditions #MLTC. Diseases including T2D, CVD, CKD and MASLD/MASH are considered a major global health challenge, driven by shared risks like obesity, insulin resistance and social disadvantage.
https://t.co/CjxoSMQ8Do

[Cristina Tejera @cristinatejerap]

Los agonistas del receptor de GLP-1 no solo bajan glucosa y peso, cada vez hay más evidencia de un efecto antiinflamatorio directo en múltiples órganos.

La inflamación crónica es el hilo que conecta diabetes, enfermedad cardiovascular, hígado y cerebro.

Revisión de esta semana en JCEM

👇 🔗 https://t.co/YuGLx7lg5v

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

New—Beyond weight loss: multisystem benefits of obesity medications https://t.co/IFPyEU8bKn
#weightloss #obesity #overweight
#GLP-1 receptor agonists

[Nature Reviews Endocrinology @NatureRevEndo]

New content online: Causes and consequences of discontinuation of GLP1RAs or tirzepatide https://t.co/QViCwUbOJJ

[Cristina Tejera @cristinatejerap]

Interesante puesta al día sobre el síndrome cardiovascular-renal-metabólico (CKM) en @NatRevNeph

Un constructo que integra lo que siempre hemos visto junto en consulta: obesidad ( enfermedad metabólica crónica adiposa), resistencia insulínica, enfermedad renal, riesgo cardiovascular, pero que al clasificar al 75-90% de los adultos como estadio ≥1 nos obliga a preguntarnos: ¿dónde está el límite entre factor de riesgo y enfermedad?

El verdadero reto, manejar todo esto en la práctica clínica diaria.

🔗 https://t.co/2bSQb7bR37

[Isa Cueto @isabellacueto]

Today, we dive into a unique liver crisis emerging in the US due to our high rates of metabolic disease (obesity, type 2 diabetes) & heavy alcohol use. That combo is driving liver disease in younger adults who may not even know the damage they're doing.
https://t.co/viJzwmdK5R

[Diabetologia @DiabetologiaJnl]

Global biobanks and data resources are transforming human islet research—linking high-quality tissues with deep phenotyping and multi-omics to reveal new diabetes mechanisms. #OpenScience is paving the way to harmonised data and personalised treatments https://t.co/iJbrynsvLQ 🔓

[Dr.Marlon Villanueva™ 🩺 𝕏 @MarlonVFZR]

https://t.co/IJX9E6sYz4